Darwin Global Management, Ltd. 13F: Quarter-over-Quarter Portfolio Changes
Darwin Global Management, Ltd. reported a disclosed portfolio value of approximately $3.8 billion in its latest SEC Form 13F-HR filing for Q1 2026, down 23.7% quarter on quarter. Over the quarter, the fund initiated 3 new positions, bought more shares in 2 holdings, trimmed 1 holding, and exited 3 positions.
Darwin Global Management, Ltd.'s top buy was a new stake in Revolution Medicines INC (RVMD) , equal to 5.4% of the disclosed portfolio. Its top sell was Insmed INC (INSM) . The fund sold 19.7% of its previously reported shares, reducing the position's portfolio weight by 5.4 percentage points.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| REVOLUTION MEDICINES INC | RVMD | 5.4% | History → |
| ROIVANT SCIENCES LTD | ROIV | 4.8% | History → |
| DIANTHUS THERAPEUTICS IN | DNTH | 0.0% | History → |
Top BuysQ1 2026
The fund's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| ABIVAX SA | ABVX | +0.4% | +9.1% | History → |
| BELITE BIO INC | BLTE | +2.2% | +1.0% | History → |
Top SellsQ1 2026
The fund's top sells among positions it retained in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| INSMED INC | INSM | -5.4% | 19.7% | History → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| CIDARA THERAPEUTICS INC | CDTX | 4.5% |
| WAVE LIFE SCIENCES LTD. | WVE | 2.5% |
| CAPRICOR THERAPEUTICS INC | CAPR | 0.5% |
Net Portfolio Value ChangeQ1 2026
- $4.9BPrior quarter
- $3.8BCurrent quarter
- $-1.2BNet delta
- -23.7%% change
Methodology & FAQ
How Darwin Global Management, Ltd. Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Darwin Global Management, Ltd.: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Darwin Global Management, Ltd. buy in Q1 2026?
In Q1 2026, Darwin Global Management, Ltd. initiated 3 new positions (REVOLUTION MEDICINES INC (RVMD), ROIVANT SCIENCES LTD (ROIV), DIANTHUS THERAPEUTICS IN (DNTH)); bought more shares of ABIVAX SA (ABVX), BELITE BIO INC (BLTE).
What stocks did Darwin Global Management, Ltd. sell in Q1 2026?
In Q1 2026, Darwin Global Management, Ltd. fully sold 3 positions (CIDARA THERAPEUTICS INC (CDTX), WAVE LIFE SCIENCES LTD. (WVE), CAPRICOR THERAPEUTICS INC (CAPR)); reduced holdings in INSMED INC (INSM).
Which positions did Darwin Global Management, Ltd. initiate in Q1 2026?
Darwin Global Management, Ltd. established 3 new positions in Q1 2026: REVOLUTION MEDICINES INC (RVMD, 5.4%), ROIVANT SCIENCES LTD (ROIV, 4.8%), DIANTHUS THERAPEUTICS IN (DNTH, 0.0%).
Which existing positions saw the largest allocation increases for Darwin Global Management, Ltd. in Q1 2026?
Of 2 existing positions with share-count increases in Q1 2026, the largest were: ABIVAX SA (ABVX, +0.4% weight, +9.1% shares), BELITE BIO INC (BLTE, +2.2% weight, +1.0% shares).
Which positions did Darwin Global Management, Ltd. fully exit in Q1 2026?
Darwin Global Management, Ltd. fully exited 3 positions in Q1 2026: CIDARA THERAPEUTICS INC (CDTX, last-reported weight 4.5%), WAVE LIFE SCIENCES LTD. (WVE, last-reported weight 2.5%), CAPRICOR THERAPEUTICS INC (CAPR, last-reported weight 0.5%).
Which existing positions saw the largest allocation reductions for Darwin Global Management, Ltd. in Q1 2026?
Of 1 existing position with share-count reductions in Q1 2026, the largest were: INSMED INC (INSM, -5.4% weight, -19.7% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.